登录新浪财经APP 搜索【信披】查看更多考评等级 2025年6月，浙江省义乌市检察院检察官"送法上门"，为外商普及知识产权保护相关法律知识。 2025年3月，浙江省杭州市滨江区检察院知识产权办案团队专题研究诉前促赔方案，破解追赃挽损难 题。 保护知识产权就是保护创新。从数字经济创新提质到具身智能、低空经济等新兴产业活力涌动，近年 来，浙江凭借"创新"一次次出圈，创新已成为高质量发展的关键变量。而浙江省检察机关也以实际行 动，切实强化新质生产力检察保护。 "在办案中，我们发现一些电子科技、生物材料等高新技术领域的企业，往往更容易遭遇侵权，相关案 件的罪责认定也更为复杂。"浙江省检察院知识产权检察部检察官吴俊洁告诉记者。 作为浙江省首批国家知识产权保护示范区、杭州国家自主创新示范区核心区，杭州市滨江区创新要素活 跃，创业产业蓬勃发展，科技创新能力持续提高，因此，侵犯知识产权案件较为频发。 "陆续有客户向国内一生产高端网络交换机的企业反映，终端机使用很不稳定，云计算服务器经常宕 机。"滨江区检察院检察官谢轶接到案件线索后，敏锐发现疑点重重、不合常理，于是督促企业立即彻 查。结果令他们大吃一惊，原来竟是企业使用了假的 ...

转自：广东阳江发布 丙午马年，烈焰翻涌，正如阳东大地新春发展之势——产业布局无限光明，全员服务热情正盛，县域经济奔腾在望，期待更多民间资本和社会力量强 势"加盟"…… 2月26日，阳东区高质量发展大会暨运营提升行动动员会将在阳东区电子电器产业园标准厂房二期举行。本次盛会以区委、区政府名义，号令全员上阵、 上下齐心，激起一马当先、马不停蹄的昂扬斗志，奋力投身构建阳东特色"1+3+3+X"现代化产业体系，以及推进中国式现代化阳东实践的伟大征程。 产业发展质效足以撼动城市经济"硬脊梁"；企业一句"好口碑"，胜过多少金杯银杯！ 紧跟阳江市"提质服务年"的工作主线，阳东立足实际，在2026年正式吹响实施"运营提升"行动的全新号角，向五湖四海的企业家发出一份合作共赢的诚挚 邀约：欢迎走进阳东、了解阳东、游历阳东、投资阳东，共建共享一个商机满满、生机勃勃的富美新阳东！ 绿能拔尖 发展指标全省领先 投资 是拉动全域经济增长的"头驾马车" 也是阳东区委、区政府 新一年实施"运营提升"行动的重中之重 "十四五"期间，阳东实现固定资产投资总额年均增长9%，其中去年表现尤其亮眼。2025年，阳东共完成固定资产投资同比增长77%，增速 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，浙江海正生物材料股份有限公司发布《股东减持股份计划公告》。公告显示，截至公告披露日， 中石化资本持有海正生材10,788,194股，占总股本的5.32%，股份来源于首次公开发行前取得。因经营 发展资金需求，中石化资本计划自公告披露之日起十五个交易日后三个月内，通过集中竞价交易方式减 持不超过2,026,700股，占公司总股本比例不超过1%。减持价格将按市场价格确定，减持期间为2026年3 月17日至2026年6月16日。本次减持计划不会导致公司控制权变更，亦不会对公司治理结构及持续经营 产生重大影响。 《浙江海正生物材料股份有限公司股东减持股份计划公告》 《浙江海正生物材料股份有限公司首次公开发行部分限售股票上市公告》 《中信建投证券股份有限公司关于浙江海正生物材料股份有限公司首次公开发行部分限售股票上 市流通的核查意见》 截至2026年2月24日收盘，海正生材（688203）报收于13.46元，较前一交易日上涨0.75%，最新总市值 为27.28亿元。该股当日开盘13.57元， ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 在生物材料设计与合成领域，如何像搭建乐高一样，将多种截然不同的生物活性功能（如抗菌、促再生、催化等）精准、牢固地"组装"到一种材料骨架 上，是实现复杂智能功能的关键挑战。细菌纤维素（BC）具备天然三维纳米纤维网络与优异生物相容性，是理想的结构基底，但其本征化学惰性使其长 期处于"功能沉默"状态。现有改性策略往往具有强耦合特征，容易在引入新功能的同时破坏材料微结构与力学/生物学性能，从而难以实现多功能模块的 协同集成与可扩展迭代。 近日，中国科学院深圳先进技术研究院定量合成生物学全国重点实验室、合成生物学研究所 钟超 研究员、 安柏霖 副研究员，联合上海科技大学 郑宜君 教授与上海长征医院 叶添文 教授团队，在国际知名期刊 Nature Communications 发表研究成果。研究团队成功构建了一种通用的"生物正交功能化"平 台，创新性地结合代谢糖工程与点击化学策略（2022年诺贝尔化学奖），将BC转化为可按需编程的"活性基座"，为其多功能集成与应用拓展开辟了新路 径。 ...

这一项目实现了从核心技术到产业化落地的多重突破。在技术层面，柏垠生物已完成多项全球领先的重 组贻贝粘蛋白相关专利布局，构建起坚实的技术壁垒，并成为国内首家完成重组贻贝粘蛋白医疗器械原 料备案的企业，牵头制定首个相关团体标准，填补行业空白。在产品转化方面，项目已实现重组贻贝粘 蛋白原料的规模化量产，并进一步延伸至系列化终端产品。2025年3月，公司获得多个以重组贻贝粘蛋 白为核心的医疗器械产品注册证，推出医用凝胶、创面敷料等国内最全系列产品，广泛应用于伤口护 理、黏膜修复等场景，为消费者提供更安全高效的解决方案。在行业影响上，项目改变了依赖自然资源 提取的传统模式，树立"绿色替代传统"标杆。通过绿色生物制造显著降低生产成本，推动高性能生物材 料普惠化，满足更广泛人群的修复需求；同时减少对海洋生态的依赖，契合"双碳"战略，为生物医药产 业的可持续发展提供新范式。 作为合成生物学领域的创新代表，柏垠生物通过重组贻贝粘蛋白绿色生物制造项目，彰显了"BT+IT"技 术融合的巨大潜力。未来，随着技术的持续迭代与产品矩阵的不断丰富，公司将继续以绿色生物制造赋 能更多传统产业，为新质生产力发展注入更多绿色动能，推动中国生物材 ...

来源：科技日报 科技日报记者 赵汉斌 记者25日从昆明理工大学获悉，该校灵长类转化医学研究院团队近期研发的一种新型动态滑环水凝胶， 集伤口监测、精准适配、药物缓释等多种功能于一体，为再生医学与精准医疗领域提供了全新解决方 案。相关研究成果发表于国际期刊《先进医疗材料》。 这种新型水凝胶，采用超分子主—客体相互作用机制构建，核心由两种自主研发的材料组分构成：一种 是四臂聚乙二醇双酪氨酸，作为客体组分；另一种是经精氨酸-甘氨酸-天冬氨酸肽功能化修饰的超支化 聚甘油修饰α-环糊精，作为主体组分。两种组分通过特殊相互作用形成动态网络结构，赋予水凝胶剪切 变稀与快速自修复的独特特性。 这种设计，让水凝胶具备了多重实用功能。在临床应用中，它可实现室温下的挤出式三维打印，精准适 配不同形状的复杂创面，解决了传统医疗材料难以贴合不规则伤口的难题。同时，水凝胶中的双酪氨酸 核心使其拥有pH响应荧光传感功能，可通过荧光强度的变化，实时反馈伤口微环境的pH值波动，为医 生及时判断伤口是否发生感染、炎症程度提供了可视化依据，避免了传统检测方法的滞后性。 此外，超支化聚甘油修饰技术的应用，显著提升了水凝胶对妥布霉素等抗菌药物的负载能力 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 近日， 珠海麦得发生物科技股份有限公司 （以下简称"麦得发"）宣布完成B轮融资，本轮融资由中国太平创新、广药资本联合注资。 据资料显示，随着合成生物学技术持续突破与生产成本逐步下降，PHA产能预计将快速提升，到2029年全球产能有望接近100万吨，约占生物降解塑料总 产能的四分之一，成为高端医疗、特种包装等场景的核心替代材料。 2026年3月31日-4月1日， " 第五届中国合成生物学及生物制造大会 " 将 在 杭州 隆重举行，其中设置 【 生物基化学品与材料专场 】 ，诚邀各位专家及相关从业者 参会交流！ 本次融资资金将 主要用于 PHA（聚羟基脂肪酸酯） 上下游管线持续研发生产、全球市场拓展及核心团队升级建设 。 据悉，麦得发成立于2019年，专注于研究、开发、生产及商业化最新一代纯生物基全域降解材料PHA及其高值健康小分子，并积极探索其在绿色健康、 医疗健康和营养健康等前沿领域的创新应用。 作为聚焦新一代纯生物基全域降解材料的创新企业，麦得发凭借自主知识产权的菌种构 ...

Core Insights - Shaanxi province is witnessing a transformation in its capital market, shifting from resource-driven growth to innovation and technology-driven development, with a focus on high-tech industries and global competitiveness [1][2][3] Group 1: Company Developments - As of January 12, 2026, Shaanxi has 84 A-share listed companies, with over half being high-tech enterprises, which are crucial for high-quality development [2] - Notable companies such as Kangtuo Medical, Nova Star Cloud, Tongli Co., and Lite Optoelectronics are emerging as leaders in their respective niches, focusing on advanced R&D and global market strategies [1][2] - Kangtuo Medical's PEEK materials are registered in nearly 40 countries, while Nova Star Cloud serves over 4,000 clients with its video solutions, showcasing the global reach of Shaanxi enterprises [2] Group 2: R&D and Investment - In 2024, the total R&D investment of A-share listed companies in Shaanxi exceeded 12 billion yuan, with an average R&D intensity of 8.75% among Sci-Tech Innovation Board companies, ranking among the top in the country [2] - The focus on high R&D intensity reflects a long-term commitment to innovation, positioning these companies for future market leadership [2][3] Group 3: Strategic Direction - Shaanxi companies are increasingly adopting a global perspective, not only expanding their markets but also exporting technology standards and brand value [2] - The development path for these companies involves overcoming technical barriers through sustained R&D, leading to market breakthroughs and ultimately enabling them to compete globally [3][4] Group 4: Innovation Ecosystem - The growth of Shaanxi's capital market is supported by initiatives like the "Qin Chuang Yuan" innovation platform and reforms in technology transfer, facilitating the conversion of academic research into industrial applications [4] - There are over 520 key listed companies in Shaanxi, with 96.54% being technology-oriented, indicating a robust pipeline of future growth in sectors like aerospace, semiconductors, and advanced materials [4]

Core Viewpoint - The article discusses the recent B-round financing of Zhuhai Maidefa Biotechnology Co., Ltd. (referred to as "Maidefa"), highlighting its unique positioning in the pharmaceutical and PHA (polyhydroxyalkanoates) materials market, and the strategic partnerships that support its growth [4][7][8]. Financing and Growth - Maidefa successfully completed its B-round financing, with investments from China Taiping Innovation and Guangzhou Pharmaceutical Capital, although the specific amount remains undisclosed [4][7]. - The company has a history of financing rounds, including an angel round in March 2021, a series A round in May 2022, and an A+ round in December 2023, indicating a steady growth trajectory [5][6]. Product Lines and Market Position - Maidefa operates three main product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate (β-HB), which together form a complete PHA value chain [14]. - The industrial-grade PHA is used in biodegradable packaging and has gained recognition from major companies like Walmart and Costco [16]. - The medical-grade PHA is a core differentiator for Maidefa, making it the world's first supplier of medical-grade PHA materials, with necessary regulatory approvals from both China and the USA [18]. - The beta-hydroxybutyrate product, branded as "Sainao Si," targets brain health and has been launched in markets including Macau and the USA [19]. Strategic Partnerships - Maidefa's third-largest shareholder is Lijun Pharmaceutical Group, which has been involved since the company's inception, indicating a deep-rooted strategic alignment in the pharmaceutical sector [10][12]. - Guangzhou Pharmaceutical Capital's investment is expected to provide not only financial support but also additional resources in the pharmaceutical domain, enhancing Maidefa's market capabilities [13]. Milestones and Future Plans - The company has achieved significant milestones, including the establishment of a cleanroom for medical-grade PHA production and the expansion of its production capacity for industrial-grade PHA [23][25]. - The successful completion of the B-round financing is seen as a new impetus for Maidefa's industrialization in the PHA sector, reinforcing its dual strategy of "pharmaceutical + PHA" [27].

Core Insights - The article discusses the emerging field of biomanufacturing, which is recognized as one of the six future industries in China's 14th Five-Year Plan, highlighting its potential to transform various sectors through innovative production methods [11][32][34]. Group 1: Definition and Process of Biomanufacturing - Biomanufacturing involves utilizing biological entities, such as microorganisms and plant or animal cells, to metabolize raw materials into desired products, effectively turning cells into small factories [5][26]. - The process includes maintaining optimal conditions for cell growth, such as temperature and pH, and providing sufficient nutrients like carbon dioxide and hydrolyzed agricultural waste [5][26]. - The production capabilities of biomanufacturing can replace traditional agricultural methods, as seen with artemisinin production, which can be synthesized in a single container rather than requiring extensive farming [32][34]. Group 2: Market Potential and Industry Growth - The biomanufacturing industry in China reached a total scale of 1.1 trillion yuan during the 14th Five-Year Plan period, indicating significant growth potential [11][32]. - China's unified large market and comprehensive manufacturing system provide a strong foundation for developing new fields such as bio-based materials and biopharmaceuticals [34]. - The integration of biomanufacturing with over two-thirds of existing industries, including traditional chemical sectors, presents opportunities for efficiency improvements and greener production methods [34]. Group 3: Technological Advancements and Innovations - Recent breakthroughs in life sciences and synthetic biology, including gene sequencing and editing technologies, are being widely applied in biomanufacturing, leading to transformative changes in production methods [9][30]. - The establishment of national key laboratories and innovation platforms has positioned China as a leader in biomanufacturing research, with over 20% of global publications and patent applications in this field [36][37]. - The development of artificial intelligence-assisted tools for synthetic biology is enhancing the efficiency of strain design and selection processes, facilitating the production of specific therapeutic compounds [34][36]. Group 4: Infrastructure and Support for Startups - The construction of pilot testing platforms is crucial for supporting biomanufacturing startups, allowing them to transition from laboratory research to large-scale production [39][41]. - Regions like Hunan are investing in infrastructure to support biomanufacturing, including a 330-acre acceleration factory set to accommodate multiple startups for large-scale production by 2026 [39][41]. - Local governments are also creating supportive regulations and funding mechanisms to foster the growth of biomanufacturing clusters, enhancing the industry's long-term viability [41]. Group 5: Future Outlook - The rapid development and market expansion of biomanufacturing in China indicate a promising future, with ongoing efforts to innovate and apply biomanufactured products across various sectors [22][43].